Our team has a breadth of expertise, and together, we attack cancer from every direction. Tempus is a technology-enabled precision medicine solutions company that has built an operating system to battle cancer. MONDAY 22 JUNE, 2020 SESSION 3: DISRUPTIVE CONCEPTS AND METHODOLOGICAL INNOVATIONS … A CBC Recruitment Resources Award was instrumental in attracting Kevin to Chicago and he later became the first CBC Senior Investigator. Tempus Labs - Cited by 38,512 - Genomics - Computation and Systems Biology ... Kevin P. White. United States. Dr White reported receiving personal fees from Tempus Labs during the conduct of the study. He was recruited to UChicago in 2006 with help of a generous CBC Resources Fund Award, and was also designated the first CBC Senior Investigator. Establishing tumor type and subtype guides standard of care treatment for several NCCN targeted therapy guidelines. Integrating Genomics and Transcriptomics to reshape Precision Oncology: A WINning Strategy: SUNDAY 21 st JUNE, 2020. Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA Background: Tumors of unknown origin account for up to 5% of newly diagnosed cancers and the average survival time is 9 to 12 months from diagnosis. Kevin White, Tempus Labs: I was really impressed with Kevin White’s GLBIO2017 talk and demo of his company’s technology (despite the ongoing technical A/V issues!) Welcome and Opening Remarks. Articles Cited by. The extraordinary team of scientists, software developers and business experts at Tempus is like no other, and I’m thrilled to help lead the team through this amazing moment in time.”. Kevin Romone White Jr. (born June 25, 1992) is an American football wide receiver for the San Francisco 49ers of the National Football League (NFL). Kevin White. Chicago, IL 60654 Genomics Computation and Systems Biology. Kevin White Tempus, Chicago, USA Integrating Genomics and Transcriptomics to reshape Precision Oncology: a WINning strategy Program www.winsymposium.org. Kevin White, currently Chief Scientific Officer of a biotech start-up Tempus Labs, is one of the co-authors on the paper. Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. Dr. Kevin White has joined Tempus as President, where he will oversee the scientific operation. “His background in cancer genomics will be a tremendous asset in leading the Tempus team.”. Jessie Cohen Executive Operations, Office of the CEO at Tempus Labs, Inc. Hailey Lefkofsky. Methods: Targeted DNA … Dr. Kevin White has joined Tempus as President, where he will oversee the scientific operation. “We are thrilled to have someone of Kevin’s reputation join Tempus, as he is a recognized leader in integrating genomics and systems biology into cancer care,” said Eric Lefkofsky, Co-founder and CEO of Tempus. Kevin White, CBC Senior Investigator, UChicago and President of Tempus Labs, contributed to a recent study in the International Journal of Cancer, which examined associations between germline variants and somatic mutation signatures in breast cancer across diverse populations and geographic locations. Join our team. Tempus Labs, Inc. operates as a clinical laboratory. Dr. Kevin White serves as President at Tempus, where he oversees the scientific operation. Verified email at tempus.com. Jessie Cohen Executive Operations, Office of the CEO at Tempus Labs, Inc. Hailey Lefkofsky. Tempus Labs. Kevin P. White Genomic analysis of paired tumor–normal samples and clinical data can be used to match patients to cancer therapies or clinical trials. We are the collective of our combined knowledge base. Nature genetics 29 (4), 389-395, 2001. Funding Innovation: A non-dilutive Approach He is a pioneer in combining experimental and computational techniques to understand the networks of factors that control biological systems during development, disease, and evolution. Correspondence to Kevin P. White. White was recruited to UChicago in 2006 with the help of a generous CBC Resources Fund Award and was also designated the first CBC Senior Investigator. Kevin White, president of Tempus and founding director of the Institute for Genomics and Systems Biology at the University of Chicago, calls Lefkofsky a quick study. Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA Background: Tumors of unknown origin account for up to 5% of newly diagnosed cancers and the average survival time is 9 to 12 months from diagnosis. Tempus, a leader in artificial intelligence and precision medicine, today announced a collaboration with Kronos Bio, Inc., to perform sequencing analysis for patients enrolled in Kronos Bio’s Phase 1/2 clinical trial of KB-0742, the company’s investigational CDK9 inhibitor. Kevin White, CBC Senior Investigator, UChicago and President of Tempus Labs, contributed to a recent study in the International Journal of Cancer, which examined associations between germline variants and somatic mutation signatures in breast cancer across diverse populations and geographic locations. We are the collective of our combined knowledge base. Tempus Labs. Kevin White, Tempus Labs: I was really impressed with Kevin White’s GLBIO2017 talk and demo of his company’s technology (despite the ongoing technical A/V issues!) Articles Cited by. Senior Vice President, Head of AI and Data Science at Tempus, Inc. Mountain View, CA. Germline genetic risk variants and carcinogenesis. Kevin White, Tempus Labs: I was really impressed with Kevin White’s GLBIO2017 talk and demo of his company’s technology (despite the ongoing technical A/V issues!) "If you want to go fast, go alone; if you want to go far, go together." Kevin White. We analyzed 500 patient samples across diverse tumor types using the Tempus xT platform by DNA-seq, RNA-seq and immunological biomarkers. Tempus is a technology-enabled precision medicine solutions company that has built an operating system to battle cancer. Jessie Cohen. All Content Copyright 2021 | Privacy Policy | Notice of Privacy Practices | Terms of Use. “His background in cancer genomics will be a tremendous asset in leading the Tempus … From 2006-2016 he was the Founding Director of the Institute for Genomics & Systems Biology at the University of Chicago. How Broad Proteomics Can Lead to More Understanding of Human Biology Larry Gold, Founder, Chairman of the Board & Former CEO of SomaLogic Growth Hack Your Future Rosemarie Truman, Founder & CEO, Board Member of The Center for Advancing Innovation. Methods: Targeted DNA … “A current limitation of the TCGA’s genomic dataset is the modest amount of follow-up clinical data that is available,” said Kevin White, President of Tempus. Dr. Kevin White serves as President at Tempus, where he oversees the scientific operation. Establishing tumor origin guides standard of care treatment for several NCCN targeted therapy guidelines. Tempus Labs serves customers in the State of Illinois. Tempus’ President, Kevin White, was recruited by the University of Chicago in 2006 and retains an appointment there as Professor at the Department of Human Genetics and Medicine. Our team has a breadth of expertise, and together, we attack cancer from every direction. "If you want to go fast, go alone; if you want to go far, go together." Greater Chicago Area. “We are living through a new era where there is a confluence of technology, data science and biology,” said Dr. White. It is on a mission to redefine how genomic data is used in a clinical setting. Germline genetic risk variants and carcinogenesis. Dr. White has served on the scientific boards of a wide range of start-up biotech companies and foundations. Data-driven precision medicine. Kevin White, PhD serves as the president while Gary Palmer, MD is the Chief Medical Officer. ... W Jin, RM Riley, RD Wolfinger, KP White, G Passador-Gurgel, G Gibson. Join our team. Tempus provides unique sequencing services and analyzes somatic and germ line molecular data with the intended therapeutic data to allow … Kevin White is Chief Science Officer at Tempus Labs Inc. See Kevin White's compensation, career history, education, & memberships. Richard L. … Suite 775 Dr. White was the founding Director of the Institute for Genomics and Systems Biology at The University of Chicago, where he retains an appointment as the James and Karen Frank Family Professor of … “Oncologists and pathologists need modern and easy-to-use tools to keep up with the ever-increasing amount of data that is being generated during the course of a patient’s treatment,” said Kevin White, President of Tempus. Eric Lefkofsky. Kevin White, Tempus Labs: I was really impressed with Kevin White’s GLBIO2017 talk and demo of his company’s technology (despite the ongoing technical A/V issues!) Arvind Prasad. Title. Richard L. … Kevin White, currently Chief Scientific Officer of biotech start-up Tempus Labs, is senior author on the Nature Biotechnology publication. “A current limitation of the TCGA’s genomic dataset is the modest amount of follow-up clinical data that is available,” said Kevin White, President of Tempus. TangoTrade enlists Tempus for payment assurance TangoTrade, a financial software provider that empowers small and medium-sized businesses (SMBs) to import and export globally, announced today the launch of its Payment AssuranceTM solution with Tempus, a leading foreign exchange (FX) and international payment solutions company. Verified email at tempus.com. Establishing tumor type and subtype guides standard of care treatment for several NCCN targeted therapy guidelines. Tempus, a health-tech company focused on helping doctors personalize cancer care, and the Robert H. Lurie Comprehensive Cancer Center of Northwestern Tempus is making precision medicine a reality through the power and promise of data and artificial intelligence. Arvind Prasad ... Kevin White. “By empowering physicians to make data-driven decisions, Tempus aims to advance precision medicine by bringing molecular insights and advanced bioinformatics to the treatment of each and every cancer patient. Jessie Cohen. “We are thrilled to have someone of Kevin’s reputation join Tempus, as he is a recognized leader in integrating genomics and systems biology into cancer care,” said Eric Lefkofsky, Co-founder and CEO of Tempus. Dr. White is the founding Director of the Institute for Genomics and Systems Biology at The University of Chicago, where he still holds an appointment as the James and Karen Frank Family Professor of Human Genetics and Medicine. Kevin White, Professor Uchicago & President of Tempus. The Company provides genomic sequencing services and analyze molecular and therapeutic data to help physicians to make real-time and data-driven decisions. In the nonprofit sector he currently holds scientific advisory board positions at institutions that include Harvard University, Yale University, Northwestern University and the National Cancer Institute. Taiki Esheim. Ethics declarations. Tempus Labs - Cited by 38,512 - Genomics - Computation and Systems Biology ... Kevin P. White. 600 West Chicago Avenue 600 West Chicago Avenue Suite 775 Chicago, IL 60654 United States. It is on a mission to redefine how genomic data is used in a clinical setting. We are a team with a singular shared goal: to improve patient outcomes. Welcome and Opening Remarks. Genomics Computation and Systems Biology. 3081 Background: Tumors of unknown origin occur in approximately 5% of newly diagnosed cancers and are difficult to treat without establishing the tissue type from which they derive. ... W Jin, RM Riley, RD Wolfinger, KP White, G Passador-Gurgel, G Gibson. Kevin White. Title. Integrating Genomics and Transcriptomics to reshape Precision Oncology: A WINning Strategy: SUNDAY 21 st JUNE, 2020. We are a team with a singular shared goal: to improve patient outcomes. Nature genetics 29 (4), 389-395, 2001. Kevin P. White Genomic analysis of paired tumor–normal samples and clinical data can be used to match patients to cancer therapies or clinical trials.